Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Strides Arcolab Gets US FDA Nod For Vancomycin Oral Capsules

Strides Arcolab Ltd. said it had received approval from the US FDA to market its generic Vancomycin Hydrochloride capsules in the strength of 125mg and 250 mg.

Vancomycin capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of last resort, used only after treatment with other antibiotics had failed.

The company plans to launch the product immediately through US-based Alvogen on a profit-sharing basis, the company said.

As per IMS health data, Vancomycin capsules had total US sales of $332 million for the twelve months ended February 12, with no prior generic approvals.

Commenting on the development, Strides Group CEO Arun Kumar said, "Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult-to-manufacture products.''

At the BSE, Strides Arcolab closed Wednesday's trading at Rs 631.90, after touching a 52-week high of Rs.649 in the early trading session.

Click here to receive FREE breaking news email alerts for Strides Arcolab Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.